Can be reimbursed. In December 2021, abeciclib was included in the Category B scope of the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021 Edition)" for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. . The price of the drug has been reduced and it has been included in Beijing's medical insurance catalog. Based on 80% reimbursement, the monthly drug cost can be reduced to less than 1,000 yuan, significantly reducing the burden on patients.